CA-XPRIZE
23.6.2021 19:32:08 CEST | Business Wire | Press release
XPRIZE , the world’s leader in designing and operating incentive competitions to solve humanity’s grand challenges, and IBM Watson , IBM’s AI technology for business, today announced the Grand Prize Winner in the $5M IBM Watson AI XPRIZE Challenge . First launched in 2016, the five-year global competition looked to accelerate adoption of artificial intelligence (AI) technologies and spark creative, innovative and audacious demonstrations of the technology that are truly scalable to solve societal grand challenges.
Winning first place honors is Zzapp Malaria , in second place is Aifred Health , followed by Marinus Analytics . These finalists were selected out of a pool of 10 semifinalists following presentations of their solutions to a panel of judges during an event held at TED headquarters in New York City last year. A $3 million grand prize, $1 million second place prize, and $500k third place prize will be awarded to the teams. In total, over 150 teams throughout the world joined the competition.
"After five years of hard work and dedication, XPRIZE is thrilled to announce Zzapp Malaria as the grand prize winner of IBM Watson AI XPRIZE,” said Anousheh Ansari, CEO of XPRIZE. “Zzapp Malaria, Aifred Health and Marinus Analytics are on the forefront of AI advancement, and we are looking forward to seeing firsthand the positive impact they will have on our future.”
"Each of the three finalists of the IBM Watson AI XPRIZE showcase what's possible when the power of AI is used to address some of the world’s toughest challenges,” said Daniel Hernandez, General Manager, IBM Data and AI. “It’s inspiring to witness how the AI technologies we developed at IBM help these organizations realize and scale their good tech solutions to drive positive societal change.”
Based out of Tel Aviv, Israel, Zzapp Malaria is committed to malaria elimination. The team’s AI technology is geared towards tackling the main challenges faced by malaria elimination campaigns by creating custom models, built with tools like IBM Watson Studio for Cloud Pak for Data, to predict the number of small water bodies caused by weather, enabling it to optimize the timing for launching larviciding operations.
- Marinus Analytics (based out of Pittsburgh, PA): A woman-owned company founded in 2014 out of Carnegie Mellon Robotics that is driven by a single social mission: To fight human trafficking. Their solution, Traffic Jam, is a suite of analytics tools that saves hours and sometimes days of investigative time to find traffickers and recover victims by quickly turning big data into actionable intelligence. Marinus Analytics has used IBM Watson Discovery and IBM Watson Assistant to extend their Traffic Jam application, aiding investigation into financial fraud and the illicit flow of proceeds to international crime groups.
- Aifred Health (based out of Montreal, Canada): A digital health company focused on clinical decision support in mental health, starting with depression. The team’s solution uses AI to learn from thousands of patients to help tailor treatment, reducing the time it takes for a patient to reach remission. IBM Watson Health is providing Aifred Health with millions of records of observational depression data to improve their ML models.
To determine the winner, XPRIZE AI convened a global jury of representatives from around the world. The jury evaluated each team based on their performance in the following four dimensions: achieved technical impact, evidenced real-world impact, scalability of real-world impact, and ethics and safety.
The winning teams were announced today in partnership with WIRED during the IBM Watson AI XPRIZE’s AI For Good fireside chat featuring Anousheh Ansari, CEO of XPRIZE, and Seth Dobrin, IBM’s Chief AI Officer. The two discussed the challenge and the importance of AI for the future of humanity. As part of their partnership with WIRED, XPRIZE opened up a public vote for the Most Inspiring Team, and Zzapp Malaria was selected as the winner. You can watch the full fireside chat and view additional content via WIRED’s content hub linked here.
About XPRIZE
XPRIZE, a 501(c)(3) nonprofit organization, is the global leader in designing and implementing innovative competition models to solve the world’s grandest challenges. Active competitions include the $100M XPRIZE Carbon Removal, $15M XPRIZE Feed the Next Billion, $10 Million XPRIZE Rainforest, $10 Million ANA Avatar XPRIZE and $5 Million XPRIZE Rapid Reskilling. For more information, visit xprize.org.
About IBM Watson
Watson is IBM’s AI technology for business, helping organizations to better predict and shape future outcomes, automate complex processes, and optimize employees’ time. Watson has evolved from an IBM Research project, to experimentation, to a scaled, open set of products that run anywhere. With more than 40,000 client engagements, Watson is being applied by leading global brands across a variety of industries to transform how people work. To learn more, visit: https://www.ibm.com/watson .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210623005848/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference5.6.2026 18:00:00 CEST | Press release
- ALYFTREK Phase 3 data on children with cystic fibrosis ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including F/F and F/MF shows 65% reached sweat chloride levels of <30 mmol/L; Vertex on track to initiate global regulatory submissions in first half of 2026 - - Long-term 96-week interim analyses from two open-label extension studies demonstrate positive safety and efficacy profile of ALYFTREK in people with cystic fibrosis ages 6 and older -- Phase 3 data on TRIKAFTA® in children 1 to <2 years also presented; Vertex has initiated global regulatory submissions - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating
Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5.6.2026 13:00:00 CEST | Press release
Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605704506/en/ K Pro, Owkin's AI scientist for biology, powered by multimodal patient data for smarter biopharma decision making. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built
DFNS Rebrands as the Core Banking Platform for Digital Assets5.6.2026 12:41:00 CEST | Press release
DFNS today announced a rebrand, marking its evolution from a wallet infrastructure to the first core banking platform for digital assets. The company is introducing a new logo, website, and market position as fintechs and institutions move their products and operations onchain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603859127/en/ Banks, fintechs, asset managers, trading firms, payment providers, market infrastructures, and clearing houses have stopped asking how to "add crypto." They're asking how to run financial products, controls, workflows, and client services on blockchain rails, with the reliability expected of core infrastructure. Some are going further still, exploring whether the blockchain can serve as the ledger itself, where an account is an onchain object rather than a row in a database. Where IBANs, virtual accounts, and blockchain wallets converge into one governed financial account. “DFNS was built
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.6.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to seventeen newly hired non-executive employees. The equity awards were granted on June 1, 2026 and consisted of options to purchase an aggregate of 157,000 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 74,700 shares. The options have an exercise price per share equal to $14.19, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restrict
Renewable Electricity, Soft Wheat Flour From Regenerative Agriculture, Initiatives to Support Local Communities: Barilla Shares These and Other Projects in “Stories of Sustainability.”5.6.2026 10:00:00 CEST | Press release
Barilla continues to advance its commitment to tastier products with less sugar and salt;An investment of 30 million euros in 2025 to quadruple photovoltaic capacity across plants, as part of a €168 million five-year plan focused on energy efficiency, renewable energy and sustainable water management.Barilla continues to expand regenerative agriculture practices across its global value chain, with over 816,000 tons of raw materials sourced through the Barilla Sustainable Farming program.4,000 tons of products donated worldwide and €2 million allocated to social causes in 2025, supporting communities across Barilla’s global footprint through food donations and social initiatives. A slimmer Tagliatelle pack that saves 150 tons of cardboard and cuts transport-related CO₂ emissions by 20%1; ready-made sauce jars made with around 65% recycled glass; the progressive scaling of regenerative agriculture practices across Barilla’s value chain and initiatives supporting inclusion and equal oppor
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom